Recent performance snapshot for Haemonetics (HAE)
Haemonetics (HAE) has been under pressure recently, with the share price showing a 1.9% decline over the past day and a 7.4% decline over the past week, despite relatively flat movement over the past month.
Over the past 3 months, the stock has logged a 28.7% decline and is down 25.6% year to date and 9.8% over the past year. This may prompt investors to compare this market performance with the company’s reported revenue and earnings profile.
See our latest analysis for Haemonetics.
At a share price of US$59.49, Haemonetics has seen short term share price pressure build into a wider trend, with a 28.8% 3 month share price decline and a 23.5% 3 year total shareholder return decline, which points to fading momentum as investors reassess growth prospects and risk.
If this kind of move has you comparing healthcare names, it could be a good moment to scan a broader set of opportunities. You can use our screener of 34 healthcare AI stocks as a starting watchlist.
With Haemonetics trading at US$59.49 alongside annual revenue of US$1.32b and net income of US$175.44m, the key question is whether recent share price weakness signals undervaluation or if the market is already fully reflecting expectations for future growth.
Most Popular Narrative: 32.4% Undervalued
At a last close of $59.49 versus a narrative fair value of $88.00, the most followed view sees meaningful upside if the long term plan plays out.
Enterprise-wide portfolio transformation, highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions, is driving substantial gross and operating margin expansion (guidance of 26–27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.
Curious what kind of revenue profile and margin lift would support that fair value, and how long it might take to show up in earnings per share, the full narrative lays out the exact assumptions behind those forecasts and the valuation multiple needed to get there.
Result: Fair Value of $88.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still real pressure points, including reliance on a few U.S. focused products and execution risk around VASCADE and the Vivasure integration, which could challenge this view.
Find out about the key risks to this Haemonetics narrative.
Next Steps
If this mix of pressure and potential leaves you undecided, take a closer look at the full picture. This can help you move quickly and form your own stance based on 5 key rewards and 1 important warning sign.
Looking for more investment ideas?
If this story has you rethinking your watchlist, do not stop here. There is a broader set of ideas worth checking before you commit fresh capital.
- Target value by scanning our 47 high quality undervalued stocks that combine quality fundamentals with prices that may sit below their estimated worth.
- Prioritize resilience with the 69 resilient stocks with low risk scores if you want companies that score well on stability and financial strength.
- Spot early opportunities using the screener containing 24 high quality undiscovered gems that highlight lesser known names with solid underlying metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com